IVVD

Invivyd, Inc. (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company founded in 2020 and based in Waltham, Massachusetts. Originally incorporated as Adagio Therapeutics, the company went public in August 2021 and later rebranded to Invivyd. The company specializes in developing monoclonal antibody therapies specifically designed to protect immunocompromised patients from infectious diseases, with its primary focus on COVID-19 prevention and treatment. Invivyd has successfully brought its lead product <b>PEMGARDA</b> to market and is actively developing next-generation antibody treatments while expanding its pipeline to include other respiratory viruses.